BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 30451732)

  • 1. Molecular Profiling of Pheochromocytoma and Abdominal Paraganglioma Stratified by the PASS Algorithm Reveals Chromogranin B as Associated With Histologic Prediction of Malignant Behavior.
    Stenman A; Svahn F; Hojjat-Farsangi M; Zedenius J; Söderkvist P; Gimm O; Larsson C; Juhlin CC
    Am J Surg Pathol; 2019 Mar; 43(3):409-421. PubMed ID: 30451732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of Immunohistochemical Expression of Apelin, Succinate Dehydrogenase B, Chromogranin B, Human Epidermal Growth Factor Receptor-2, Contactin 4, and Succinyl-CoA Synthetase Subunit Beta in Differentiating Metastatic From Non-Metastatic Pheochromocytoma and Paraganglioma.
    Wang Y; Chen D; Pang Y; Xu X; Guan X; Liu L
    Front Endocrinol (Lausanne); 2022; 13():882906. PubMed ID: 35574028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Over-diagnosis of potential malignant behavior in MEN 2A-associated pheochromocytomas using the PASS and GAPP algorithms.
    Stenman A; Zedenius J; Juhlin CC
    Langenbecks Arch Surg; 2018 Sep; 403(6):785-790. PubMed ID: 29779047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective application of the pathologic tumor-node-metastasis classification system for pheochromocytoma and abdominal paraganglioma in a well characterized cohort with long-term follow-up.
    Stenman A; Zedenius J; Juhlin CC
    Surgery; 2019 Nov; 166(5):901-906. PubMed ID: 31239074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disentangling of Malignancy from Benign Pheochromocytomas/Paragangliomas.
    Kim KY; Kim JH; Hong AR; Seong MW; Lee KE; Kim SJ; Kim SW; Shin CS; Kim SY
    PLoS One; 2016; 11(12):e0168413. PubMed ID: 27992508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis.
    Strong VE; Kennedy T; Al-Ahmadie H; Tang L; Coleman J; Fong Y; Brennan M; Ghossein RA
    Surgery; 2008 Jun; 143(6):759-68. PubMed ID: 18549892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Value of Histological Algorithms to Predict the Malignancy Potential of Pheochromocytomas and Abdominal Paragangliomas-A Meta-Analysis and Systematic Review of the Literature.
    Stenman A; Zedenius J; Juhlin CC
    Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30769931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of malignant behavior of pheochromocytomas and paragangliomas using immunohistochemical techniques.
    Kumaki N; Kajiwara H; Kameyama K; DeLellis RA; Asa SL; Osamura RY; Takami H
    Endocr Pathol; 2002; 13(2):149-56. PubMed ID: 12165664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems.
    Wachtel H; Hutchens T; Baraban E; Schwartz LE; Montone K; Baloch Z; LiVolsi V; Krumeich L; Fraker DL; Nathanson KL; Cohen DL; Fishbein L
    J Clin Endocrinol Metab; 2020 Dec; 105(12):e4661-70. PubMed ID: 32877928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of Contactin 4 Is Associated With Malignant Behavior in Pheochromocytomas and Paragangliomas.
    Evenepoel L; van Nederveen FH; Oudijk L; Papathomas TG; Restuccia DF; Belt EJT; de Herder WW; Feelders RA; Franssen GJH; Hamoir M; Maiter D; Ghayee HK; Shay JW; Perren A; Timmers HJLM; van Eeden S; Vroonen L; Aydin S; Robledo M; Vikkula M; de Krijger RR; Dinjens WNM; Persu A; Korpershoek E
    J Clin Endocrinol Metab; 2018 Jan; 103(1):46-55. PubMed ID: 28938490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges in Paragangliomas and Pheochromocytomas: from Histology to Molecular Immunohistochemistry.
    Juhlin CC
    Endocr Pathol; 2021 Jun; 32(2):228-244. PubMed ID: 33768452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases.
    Thompson LD
    Am J Surg Pathol; 2002 May; 26(5):551-66. PubMed ID: 11979086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-210 May Be a Preoperative Biomarker of Malignant Pheochromocytomas and Paragangliomas.
    Ruff SM; Ayabe RI; Malekzadeh P; Good ML; Wach MM; Gonzales MK; Tirosh A; Nilubol N; Pacak K; Kebebew E; Patel D
    J Surg Res; 2019 Nov; 243():1-7. PubMed ID: 31146085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptome Analysis of lncRNAs in Pheochromocytomas and Paragangliomas.
    Job S; Georges A; Burnichon N; Buffet A; Amar L; Bertherat J; Bouatia-Naji N; de Reyniès A; Drui D; Lussey-Lepoutre C; Favier J; Gimenez-Roqueplo AP; Castro-Vega LJ
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31678991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients.
    Currás-Freixes M; Inglada-Pérez L; Mancikova V; Montero-Conde C; Letón R; Comino-Méndez I; Apellániz-Ruiz M; Sánchez-Barroso L; Aguirre Sánchez-Covisa M; Alcázar V; Aller J; Álvarez-Escolá C; Andía-Melero VM; Azriel-Mira S; Calatayud-Gutiérrez M; Díaz JÁ; Díez-Hernández A; Lamas-Oliveira C; Marazuela M; Matias-Guiu X; Meoro-Avilés A; Patiño-García A; Pedrinaci S; Riesco-Eizaguirre G; Sábado-Álvarez C; Sáez-Villaverde R; Sainz de Los Terreros A; Sanz Guadarrama Ó; Sastre-Marcos J; Scolá-Yurrita B; Segura-Huerta Á; Serrano-Corredor Mde L; Villar-Vicente MR; Rodríguez-Antona C; Korpershoek E; Cascón A; Robledo M
    J Med Genet; 2015 Oct; 52(10):647-56. PubMed ID: 26269449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical Expression of Choline Acetyltransferase and Catecholamine-Synthesizing Enzymes in Head-and-Neck and Thoracoabdominal Paragangliomas and Pheochromocytomas.
    Kimura N; Shiga K; Kaneko KI; Oki Y; Sugisawa C; Saito J; Tawara S; Akahori H; Sogabe S; Yamashita T; Takekoshi K; Naruse M; Katabami T
    Endocr Pathol; 2021 Dec; 32(4):442-451. PubMed ID: 34743284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas.
    Pierre C; Agopiantz M; Brunaud L; Battaglia-Hsu SF; Max A; Pouget C; Nomine C; Lomazzi S; Vignaud JM; Weryha G; Oussalah A; Gauchotte G; Busby-Venner H
    Virchows Arch; 2019 Jun; 474(6):721-734. PubMed ID: 30868297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flow cytometric DNA analysis for the determination of malignant potential in adrenal and extra-adrenal pheochromocytomas or paragangliomas.
    Pang LC; Tsao KC
    Arch Pathol Lab Med; 1993 Nov; 117(11):1142-7. PubMed ID: 8239937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and epigenetic differences of benign and malignant pheochromocytomas and paragangliomas (PPGLs).
    Khatami F; Mohammadamoli M; Tavangar SM
    Endocr Regul; 2018 Jan; 52(1):41-54. PubMed ID: 29453919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in the management of pheochromocytoma and paraganglioma.
    Tanabe A; Naruse M
    Hypertens Res; 2020 Nov; 43(11):1141-1151. PubMed ID: 32778780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.